Lantern Pharma proposes 50M authorized common shares
Lantern Pharma Inc. seeks stockholder approval to increase authorized common shares from 25M to 50M and issue up to 3.67M shares via warrants. The proposal, part of seven items on the December 1, 2026 agenda, may dilute shares if approved. As of October 5, 2026, 14.94M shares were outstanding.
How this was made
The 30-second read
Why it matters
The proposal could increase the share count, leading to dilution, but also provides flexibility for future equity compensation and financing.
Market read
A routine corporate governance filing with modest trading relevance for LTRN shareholders ahead of the annual meeting.
What to watch
The warrant exercise price of $1.09 may be attractive if the share price rises above that level.
Background
Lantern Pharma (NASDAQ:LTRN) is a micro‑cap biotech that filed a Schedule 14A proxy statement outlining several shareholder proposals, including a stock‑authorization amendment.
Ticker impact
Lantern Pharma filed a proxy statement proposing to double its authorized common shares to 50 million and issue up to 3.67 M warrant shares, pending shareholder approval at the Dec 1, 2026 meeting.
likely modest downside as market prices in possible dilution
The filing is a routine corporate action with limited immediate financial impact; investors may adjust positions ahead of the vote.
Market effects
Minimal effect on the broader biotech sector; similar small‑cap companies may see comparable dilution concerns.
Limited to U.S. over‑the‑counter biotech investors.
Low
Counterpoint
If the dilution is viewed as financing for future growth, the stock could rally on optimism.
Key entities
- companyLantern Pharma Inc.
Biotech firm seeking shareholder approval to increase authorized shares.
- service_providerEisnerAmper LLP
Proposed independent registered public accounting firm.
